Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders Sells 2,635 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 2,635 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $119,629.00. Following the sale, the chief financial officer now owns 96,470 shares in the company, valued at $4,379,738. This trade represents a 2.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jack Anders also recently made the following trade(s):

• On Friday, October 11th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The shares were sold at an average price of $50.30, for a total transaction of $503,000.00.

Revolution Medicines Price Performance

Shares of RVMD traded down $2.16 during mid-day trading on Wednesday, reaching $43.00. 1,019,225 shares of the company’s stock were exchanged, compared to its average volume of 1,392,216. The business’s fifty day simple moving average is $52.23 and its 200-day simple moving average is $46.05. Revolution Medicines, Inc. has a 52-week low of $25.60 and a 52-week high of $62.40. The stock has a market capitalization of $7.23 billion, a PE ratio of -11.98 and a beta of 1.40.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, November 6th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.05). During the same period last year, the business posted ($0.99) EPS. Equities research analysts predict that Revolution Medicines, Inc. will post -3.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in Revolution Medicines by 55.8% in the 3rd quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock valued at $28,000 after buying an additional 222 shares during the period. Quarry LP purchased a new position in Revolution Medicines during the third quarter worth about $82,000. Values First Advisors Inc. purchased a new stake in Revolution Medicines in the 3rd quarter valued at approximately $93,000. Nisa Investment Advisors LLC increased its position in Revolution Medicines by 10.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock worth $131,000 after purchasing an additional 320 shares during the period. Finally, KBC Group NV raised its stake in shares of Revolution Medicines by 12.9% during the 3rd quarter. KBC Group NV now owns 3,221 shares of the company’s stock worth $146,000 after buying an additional 368 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on RVMD. Oppenheimer boosted their target price on Revolution Medicines from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Piper Sandler boosted their price target on shares of Revolution Medicines from $57.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their price objective on shares of Revolution Medicines from $63.00 to $71.00 and gave the company an “overweight” rating in a report on Tuesday, December 3rd. HC Wainwright boosted their target price on shares of Revolution Medicines from $64.00 to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $68.00 price target on shares of Revolution Medicines in a research note on Tuesday, December 3rd. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $63.67.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.